KR101501381B1 - A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity - Google Patents
A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity Download PDFInfo
- Publication number
- KR101501381B1 KR101501381B1 KR20130126237A KR20130126237A KR101501381B1 KR 101501381 B1 KR101501381 B1 KR 101501381B1 KR 20130126237 A KR20130126237 A KR 20130126237A KR 20130126237 A KR20130126237 A KR 20130126237A KR 101501381 B1 KR101501381 B1 KR 101501381B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- composition
- present
- fat
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 90
- 241000730085 Dracontomelon macrocarpum Species 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000000694 effects Effects 0.000 title abstract description 37
- 230000003579 anti-obesity Effects 0.000 title abstract description 23
- 208000008589 Obesity Diseases 0.000 claims abstract description 41
- 235000020824 obesity Nutrition 0.000 claims abstract description 41
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 150000002632 lipids Chemical class 0.000 claims abstract description 8
- 239000002243 precursor Substances 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000004069 differentiation Effects 0.000 abstract description 9
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 102000004882 Lipase Human genes 0.000 abstract description 7
- 108090001060 Lipase Proteins 0.000 abstract description 7
- 208000010706 fatty liver disease Diseases 0.000 abstract description 7
- 208000004930 Fatty Liver Diseases 0.000 abstract description 6
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 6
- 239000004367 Lipase Substances 0.000 abstract description 6
- 235000013373 food additive Nutrition 0.000 abstract description 6
- 239000002778 food additive Substances 0.000 abstract description 6
- 235000019421 lipase Nutrition 0.000 abstract description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract description 3
- 210000000496 pancreas Anatomy 0.000 abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 24
- 235000013305 food Nutrition 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 230000036541 health Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000004132 lipogenesis Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000871543 Dracontomelon Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 229940040461 lipase Drugs 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019626 lipase activity Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000009815 adipogenic differentiation Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- -1 patches Substances 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- YNGNVZFHHJEZKD-UHFFFAOYSA-N (4-nitrophenyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 YNGNVZFHHJEZKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-M D-tartrate(1-) Chemical compound OC(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-M 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021925 Inferiority complex Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Abstract
Description
본 발명은 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum, 이하 DM이라 약칭한다)을 포함하는 항비만 조성물에 관한 것으로, 보다 구체적으로 본 발명은 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum, DM) 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 및 상기 DM 추출물을 유효성분으로 포함하는 비만 예방 또는 개선용 식품 첨가용 조성물에 관한 것이다.
The present invention relates to an anti-obesity composition comprising Dracontomelon macrocarpum (hereinafter abbreviated as DM). More specifically, the present invention relates to an anti-obesity composition comprising Dracontomelon macrocarpum (DM) A composition for preventing or treating obesity and a composition for preventing or ameliorating obesity comprising the DM extract as an active ingredient.
비만 (obesity) 또는 비만증은 사람의 몸무게가 지나치게 많이 나가는 것을 통틀어 부르는 말로서 병리학적으로는 세계보건기구 (WHO)에서 정한 이른바 표준 몸무게 기준치 (body mass index; BMI)가 30 이상인 경우를 일컫지만 한국에서는 25 이상이면 비만으로 진단한다. 대부분의 경우 체중이 정상치보다 많이 나가는 것을 뜻하지만 체중이 그다지 많이 나가지 않더라도 몸의 구성성분 중 지방의 비율이 높은 경우 비만이라고 한다. 비만은 그 자체로서는 문제가 되지 않을 수도 있으나, 이로 인해 야기되는 사회적 장애 및 과다한 지방으로 유발되는 2차 합병증이 심각하다. 예를 들어 비만은 고지혈증, 고혈압, 동맥경화, 당뇨병, 지방간, 관절이상 등의 발생 비율을 현저하게 증가시킬 수 있다.Obesity or obesity refers to the excess weight of a person's body weight, which is pathologically referred to as the World Health Organization's (WHO) standard body mass index (BMI) of 30 or more. If it is 25 or more, it is diagnosed as obesity. In most cases, weight means more than normal, but even if you do not have a lot of weight, the proportion of fat in your body is high. Obesity may not be a problem in itself, but it has serious social problems and secondary complications caused by excessive fat. For example, obesity can significantly increase the incidence of hyperlipidemia, hypertension, arteriosclerosis, diabetes, fatty liver, joint disorders, and the like.
이와 같이 비만은 각종 성인병의 원인이 된다. 체중이 늘면 혈당처리 능력이 떨어져 당뇨병을 일으키기 쉬우며 고혈압도 발생할 수 있다. 체중이 정상 체중보다 20% 증가되면 당뇨병 발병 가능성은 정상인의 10배로 증가한다. 또한 심장 및 폐 기능이 약해져서 수명이 단축될 수도 있다. 고혈압, 당뇨병, 고콜레스테롤혈증, 동맥경화증 등의 복합적인 요인들이 심장기능에 압박을 주어 심부전증에 빠지고 돌발사를 유발하기도 한다. 여성의 경우는 여기에 더해 자궁내막암의 발병률이 높아지며 담석증이 생길 가능성도 높아진다. 남성에게는 대장암과 전립선암의 발병 확률이 높아진다. 뿐만 아니라, 체중이 증가하면 남들이 자신을 바라보는 시선을 의식하지 않을 수 없고 이에 대한 강박관념이 심해지면 사람들을 기피하고 혼자만 지내려는 증상이 생긴다. 또 신체에서 오는 열등감이 자신의 삶에 대한 자신감을 잃게 하여 자아에까지 영향을 미친다.As such, obesity causes various adult diseases. Increased weight can lead to diabetes and lower blood sugar, which can lead to hypertension. If the body weight is 20% higher than normal weight, the likelihood of developing diabetes increases to 10 times that of normal people. In addition, cardiovascular and pulmonary function may be impaired and life expectancy may be shortened. Complex factors such as hypertension, diabetes, hypercholesterolemia, and atherosclerosis may put pressure on the heart function and lead to heart failure and sudden death. In addition to women, the incidence of endometrial cancer is high, and cholelithiasis is more likely to occur. Men are more likely to develop colon cancer and prostate cancer. In addition, as the weight increases, people can not help but be conscious of the gaze that they are looking at, and if the obsession about it becomes worse, the symptoms of avoiding people and living alone are generated. The inferiority feeling that comes from the body also affects the self by losing confidence in his life.
이러한 비만을 예방하고 건강 체중을 유지하기 위해서는 균형 잡힌 식사와 규칙적인 운동으로 평생 동안 꾸준히 관리해야 한다. 특히 지방세포는 한번 만들어지면 크기는 줄일 수 있지만 자연적으로 제거하는 것은 불가능하여 영구적으로 인체에 남아있게 되므로 처음부터 비만이 되지 않도록 예방하는 것이 중요하다. 따라서 일차적으로는 섭취하는 칼로리의 양을 줄이고 활동 및 운동량을 증가시키는 방법으로 체중을 줄일 수 있다.In order to prevent obesity and maintain a healthy weight, balanced diet and regular exercise should be maintained throughout the lifetime. In particular, fat cells can be reduced in size once they are made, but it is impossible to remove them naturally and it is left permanently in the human body, so it is important to prevent obesity from beginning. Therefore, weight loss can be reduced primarily by reducing the amount of calories consumed and increasing activity and exercise.
그러나 상기한 바와 같이 일단 형성된 지방세포는 제거가 불가능하므로, 다이어트 식이 섭취와 더불어 지방흡수를 감소시키는 등의 약물을 복용하는 경우가 있다. 그러나 이러한 다이어트 약은 고혈압 등의 심혈관계질환 및 뇌졸중과 같은 부작용을 유발할 수 있으며, 복용을 중단할 경우 다시 체중이 증가하는 경우가 빈번하다. 중증 비만의 경우 수술요법을 시행할 수 있으며, 이러한 수술요법으로는 지방을 제거하는 수술이나 몸이 소화할 수 있는 음식량을 제한하기 위한 위성형술 또는 위밴드삽입술 등이 시행되고 있다.
However, as described above, since the fat cells once formed can not be removed, there are cases where a drug such as a diet meal intake and a fat absorption reduction is taken. However, such diet drugs can cause side effects such as cardiovascular disease and stroke, such as hypertension, and frequently increase in weight again when stopped. In the case of severe obesity, surgical treatment can be performed. Such surgery is performed by surgery to remove fat or gastroplasty or gastric banding to limit the amount of food that can be digested by the body.
이러한 배경 하에서, 본 발명자들은 항비만 효과를 나타내면서 부작용이 적은 천연물을 찾고자 예의 연구 노력한 결과, 중국 유래 자생 식물 중 하나인 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum) 추출물이 지방세포로의 분화를 억제하여 중성지방 생성율을 감소시킬 뿐만 아니라, 췌장 리파아제 효소 활성을 억제시키는 것을 확인하고 본 발명을 완성하였다.
Under these circumstances, the inventors of the present invention have made intensive studies to find natural products having an anti-obesity effect and low side effects. As a result, it has been found that Dracontomelon macrocarpum extract, one of Chinese native plants, inhibits the differentiation into adipocytes, The present invention has been accomplished by confirming that it inhibits the activity of pancreatic lipase enzyme as well as reducing the fat production rate.
본 발명의 하나의 목적은 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum) 추출물을 포함하는 비만 예방 또는 치료용 약학 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of obesity comprising Dracontomelon macrocarpum extract.
본 발명의 다른 목적은 상기 드라콘토멜론 마크로카펌 추출물을 유효성분으로 포함하는 비만 예방 또는 개선용 식품 첨가용 조성물을 제공하는 것이다.
It is another object of the present invention to provide a composition for preventing or ameliorating obesity, which comprises the extract of Draconto melon mark Lokamer as an active ingredient.
본 발명자들은 항비만 효과를 나타내면서 부작용이 적은 천연물을 찾고자 다양한 천연물을 대상으로 연구를 수행하던 중, 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum, DM)에 주목하게 되었다.The present inventors focused on Dracontomelon macrocarpum (DM) while carrying out research on various natural products in order to find a natural product having an anti-obesity effect and a low side effect.
상기 DM을 메탄올로 추출하여 DM 추출물을 제조하고, 상기 DM 추출물의 항비만 효과를 시험한 결과, 상기 DM 추출물은 지방전구세포에 대하여 세포독성을 나타내지 않으면서도, 췌장에서 분비되는 리파아제에 대하여 저해활성을 나타내고, 지방전구세포가 지방세포로 분화되는 것을 억제하고, 지방세포내에서 중성지방의 생성을 억제함을 확인하였다.As a result of testing the anti-obesity effect of the DM extract, the DM extract showed inhibitory activity against the lipase secreted from the pancreas without showing cytotoxicity against the lipid precursor cells, And inhibited the differentiation of adipose precursor cells into adipocytes and inhibited the production of triglycerides in adipocytes.
이처럼, 상기 DM 추출물은 리파아제에 대하여 저해활성을 나타내고, 지방세포의 분화를 억제할 뿐만 아니라 지방세포에서 중성지방의 생성을 억제하는 효과를 나타내므로, 비만의 예방, 치료 또는 개선에 사용될 수 있음을 알 수 있었다.
As described above, the DM extract exhibits an inhibitory activity against lipase and inhibits the differentiation of adipocytes as well as inhibits the production of triglycerides in adipocytes. Therefore, it can be used for preventing, treating or improving obesity Could know.
상기 목적을 달성하기 위한 일 실시양태로서, 본 발명은 DM 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물을 제공한다.
In one embodiment, the present invention provides a pharmaceutical composition for preventing or treating obesity comprising DM extract as an active ingredient.
본 발명의 용어 "비만 (obesity)"은 체지방이 과도한 상태를 말하는 것으로, 임상적으로 체질량지수가 한국의 경우 25, 세계보건기구 (WHO)에 의하면 30 이상인 경우를 의미한다. 이때 체질량지수 (body mass index; BMI)는 신장의 제곱에 대한 체중 (㎏/m2)으로 계산된다. 일반적으로 체중이 정상치보다 높은 경우를 의미하지만 체중이 많이 나가지 않더라도 몸의 구성성분 중 체지방의 비율이 높은 경우 비만이라고 진단하며, 성인과 어린이 모두에서 발병하는 질환이다. 비만은 생명을 단축시키며, 고혈압, 당뇨, 심장질환 및 일부 암과 같은 질환에 걸릴 위험에 처하게 할 수 있다. 비만인 경우 건강에 문제가 생길 확률이 높으며 비만의 정도가 증가할수록 위험성 또한 높아진다. 비만이 생기는 이유는 매우 다양하며 여러 가지 원인이 복합적으로 작용하는 경우가 많다. 이 중 가장 빈번한 원인은 유전적 영향, 생리적 영향, 음식섭취와 섭식장애, 생활방식, 체중력, 임신, 및 약물 등이다. 비만의 첫 번째 징후는 평균을 웃도는 체중 이상이며 증상은 다음과 같다: 수면문제, 수면무호흡, 호흡 짧아짐, 정맥류, 피부문제, 담석 또는 체중부하로 인한 골관절염 등. 비만은 또한 고혈압을 비롯한 고혈당 (당뇨), 고콜레스테롤혈증, 고중성지방혈증 등의 질환과 관련이 있다. 한번 과체중이 되면 그 상태를 벗어나기가 쉽지 않으므로 비만은 대부분 평생 겪게 된다. 하지만 비만에 의해 생긴 질병이나 문제는 체중이 감소되면 호전될 수 있다.The term "obesity " of the present invention refers to an excessive state of body fat, which means that the body mass index is clinically 25 in the case of Korea and 30 or more according to the World Health Organization (WHO). The body mass index (BMI) is calculated as the body weight (kg / m 2 ) relative to the height of the kidney. Generally, it means that the body weight is higher than the normal value. However, when the body fat percentage of the body composition is high, even if the body weight does not go out, it is diagnosed as obesity. Obesity can shorten life and put you at risk for diseases like hypertension, diabetes, heart disease and some cancers. Obesity is likely to cause health problems, and as the degree of obesity increases, the risk also increases. Obesity is caused by a wide variety of reasons and many causes are often combined. The most frequent causes are genetic influences, physiological effects, food intake and eating disorders, lifestyle, weight, pregnancy, and medications. The first signs of obesity are above average weight, and the symptoms are: sleep problems, sleep apnea, shortness of breath, varicose veins, skin problems, osteoarthritis caused by gallstones or weight loss, Obesity is also associated with diseases such as hypertension, hyperglycemia (diabetes), hypercholesterolemia, and hypertriglyceridemia. Once you are overweight, it is not easy to get out of it, so obesity is a lifelong experience. However, diseases or problems caused by obesity can improve if weight is reduced.
이하 본 발명에서는 "항비만 (anti-obesity)" 이라는 용어를 비만 예방, 치료 또는 개선을 모두 포함하는 의미로 사용한다. 이에 따라, 본 발명에서 사용되는 "항비만 조성물"이라는 용어는 상기 비만 예방 또는 치료용 약학 조성물을 의미한다.Hereinafter, the term "anti-obesity " is used in the present invention to mean prevention, treatment, or improvement of obesity. Accordingly, the term "anti-obesity composition" used in the present invention means a pharmaceutical composition for preventing or treating obesity.
본 발명에서, 용어 "예방"이란 본 발명에 따른 약학적 조성물의 투여에 의해 비만의 발병을 억제 또는 지연시키는 모든 행위를 의미하고, "치료"란 상기 약학적 조성물의 투여에 의해 비만의 의심 및 발병 개체의 증상이 호전되거나 이롭게 변경하는 모든 행위를 의미한다.
In the present invention, the term "prevention" means any action which inhibits or delays the onset of obesity by the administration of the pharmaceutical composition according to the present invention, and "treatment" Means any action that alters or alleviates symptoms of an onset individual.
본 발명의 용어 "드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum, DM)"은 아나카르디아시에 (Anacardiaceae) 과에 속하는 종자식물이다. 캄보디아, 베트남, 중국 남부에 분포한다. DM이 속하는 드라콘토멜론 중에 가장 일반적으로 식용하는 종은 드라콘토멜론 듀퍼레아넘 (Dracontomelon duperreanum)이며, 캄보디아, 베트남, 중국에서 식용되는 과일을 생산한다. DM의 일반적인 높이는 18 미터이고, 말단의 작은 가지는 회색에서 갈색이며, 가지에서 돋아 나오는 하얀 피목과 함께 미세하게 부드러운 짧은 털로 덮여 있거나 털 없이 매끈하게 돋아 있다. 잎자루와 잎대는 얇고 매끄러운 원통형이며, 회색에서 노란색의 털이 나기 시작한다. 잎새는 50 ㎝까지 자라며, 추가의 작은 잎이 있기 때문에 잎자루가 뻗어 자란 깃축의 좌우에 작은 잎이 달려 좌우 대칭의 깃모양 우상복엽을 이루고 있지 않다. 작은 잎꼭지는 4-6 ㎜이며, 자세히 보면 회색으로 털이 나기 시작하며, 위쪽으로 홈이 파져 있다. 작은 잎꼭지 잎새는 길쭉하며, 매우 비대칭적으로 대략 9 x 2.5 ㎝ 정도이다. DM은 아직까지 구체적인 효능에 대해서는 알려진 바가 없으며, 특히 항비만 효과에 대해서는 전혀 알려진 바가 없었다. 이에 본 발명자들은 상기 DM 추출물이 항비만 효과가 있음을 확인하고, 이를 식품 또는 의약품에 적용할 수 있음을 확인하였다.
The term " Dracontomelon macrocarpum ( DM) "of the present invention is a seed plant belonging to the family Anacardiaceae . It is distributed in Cambodia, Vietnam and southern China. Among the Draconto melons to which the DM belongs, the most commonly edible species is Draconomonon duperreanum , which produces edible fruits in Cambodia, Vietnam and China. The typical height of DM is 18 meters, the small branch at the end is gray to brown, covered with finely soft short hair with smooth white sprouting from the branches, or smooth hairless. The petiole and leaf stand are thin and smooth cylindrical, gray to yellow hairs begin to appear. Leaves grow up to 50 ㎝, and there are additional small leaves, so there are small leaves on the left and right sides of the feathers growing on the petiole, and they do not form symmetrical pinnate leaves. The small petals are 4-6 ㎜ in size, and when viewed in detail, they begin to gray in color and have grooves on the top. The petiole leaflets are elongated and very asymmetrically about 9 x 2.5 cm. DM has not yet been known for its specific efficacy, especially for its anti-obesity effect. Thus, the present inventors confirmed that the DM extract had an anti-obesity effect and could apply it to foods or medicines.
본 발명의 용어 "추출물"은 생약을 적절한 침출액으로 짜내고 침출액을 증발시켜 농축한 제제를 의미하는 것으로, 이에 제한되지는 않으나, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다.The term "extract " of the present invention means a preparation which is obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating the liquid by evaporating the leaching solution, and is not limited thereto. The extract is obtained by drying the extract, diluted solution, Dried products, controlled products thereof or purified products thereof.
본 발명에 있어서, 상기 추출물은 추출용매로 추출하거나 추출용매로 추출하여 제조한 추출물에 분획용매를 가하여 분획함으로써 제조할 수 있다. 상기 추출용매는 이에 제한되지는 않으나, 물, 유기용매 또는 이들의 혼합용매 등을 사용할 수 있으며, 상기 유기용매는 탄소수 1 내지 4의 알코올이나, 에틸아세테이트 또는 아세톤 등의 극성용매, 헥산 또는 디클로로메탄의 비극성용매 또는 이들의 혼합용매를 사용할 수 있다. 또한, 바람직하게는 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매를 사용할 수 있다. 본 발명의 일 실시예에서는 상기 용매로서 95% 메탄올을 이용한 추출물을 제조하였다.In the present invention, the extract may be prepared by extracting with an extraction solvent or extracting with an extraction solvent, followed by fractionation with a fraction solvent. The extraction solvent may be, but is not limited to, water, an organic solvent or a mixed solvent thereof. The organic solvent may be an alcohol having 1 to 4 carbon atoms, a polar solvent such as ethyl acetate or acetone, hexane or dichloromethane Non-polar solvents or mixed solvents thereof may be used. Further, water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be preferably used. In one embodiment of the present invention, an extract using 95% methanol as the solvent was prepared.
상기 DM 추출물은 당업계에 공지된 일반적인 추출방법, 분리 및 정제방법을 이용하여 제조할 수 있다. 상기 추출방법으로는, 이에 제한되지는 않으나, 바람직하게 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있다.
The DM extract can be prepared by using common extraction, isolation and purification methods known in the art. The extraction method may be, but not limited to, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction.
본 발명의 용어 “드라콘토멜론 마크로카펌 (DM) 추출물”은 DM의 다양한 부분, 즉 DM의 잎, 줄기 및 꽃 중 일부 또는 전부를 포함하는 시료로부터 추출하여 수득한 추출물을 의미한다.
The term " Draconto melon marcormacum (DM) extract " of the present invention means an extract obtained by extracting various parts of DM, that is, a sample containing some or all of leaves, stems and flowers of DM.
본 발명의 구체적인 일 실시예에 의하면 (실시예 1), 본 발명의 DM 추출물은 일정 중량의 DM을 분말로 파쇄하고 5 내지 10배의 용매를 가하여 추출하였다. 용매로는 유기용매를 사용할 수 있으며, 상기 유기용매는 C1 내지 C4의 저급 알코올 또는 이들의 혼합용매일 수 있고, 바람직하게는 메탄올일 수 있다. 또한 상기 추출은 바람직하게 65 내지 85 ℃의 온도에서 수행될 수 있으며, 보다 바람직하게 75 ℃에서 수행될 수 있다. 상기 추출은 수회 반복하여 수행되었으며, 추출한 시료는 여과 후 감압농축기로 농축하고 동결 건조하였다.
According to one embodiment of the present invention (Example 1), the DM extract of the present invention is prepared by disintegrating a certain amount of DM into powder and extracting it with 5 to 10 times of a solvent. As the solvent, an organic solvent may be used, and the organic solvent may be a C1 to C4 lower alcohol or a mixture thereof, preferably methanol. Further, the extraction can be preferably carried out at a temperature of 65 to 85 캜, and more preferably at 75 캜. The extraction was repeated several times, and the extracted sample was filtered, concentrated by a vacuum concentrator, and lyophilized.
본 발명의 다른 일 실시예에 의하면 (실시예 2), DM 추출물의 농도별 처리를 통하여, 본 발명의 DM 추출물이 리파아제의 활성을 농도 의존적으로 유의적으로 억제시키는 것을 확인하였다(도 1). 리파아제의 활성이 억제되면 음식물을 통해 섭취된 지방의 체내 유입을 억제할 수 있으므로, 결과적으로는 비만을 예방 또는 치료하는 효과를 나타낼 수 있다.
According to another embodiment of the present invention (Example 2), it was confirmed that the DM extract of the present invention significantly inhibited the lipase activity in a concentration-dependent manner through treatment of the concentration of DM extracts (Fig. 1). When the activity of lipase is inhibited, the inflow of the fat ingested through the food can be inhibited, and consequently, the effect of preventing or treating obesity can be exhibited.
본 발명의 또다른 일 실시예에 의하면 (실시예 3), 본 발명의 항비만 조성물은 생체에서 안전하게 사용할 수 있는 지 여부를 확인하였다. 구체적으로 DM 추출물의 세포 독성 분석을 실시하여 세포 생존율을 담체를 처리한 대조군에 대한 %로 나타낸 결과, DM 추출물은 100 ㎍/㎖의 농도 까지 세포 독성을 전혀 유발하지 않는 안전한 물질임을 확인하였다 (도 2).
According to another embodiment of the present invention (Example 3), it has been confirmed whether the anti-obesity composition of the present invention can be safely used in vivo. Specifically, the cytotoxicity analysis of DM extracts was performed and the cell survival rate was expressed as a percentage of the control group treated with the carrier. As a result, it was confirmed that the DM extract was a safe substance which did not induce any cytotoxicity up to a concentration of 100 μg / ml 2).
본 발명의 또 다른 일 실시예에 의하면 (실시예 5), 본 발명의 항비만 조성물이 지방생성관련 단백질에 어떠한 영향을 미치는지 분석하였다. 구체적으로, DM 추출물을 다양한 농도로 처리한 지방세포에서 지방생성에 관여하는 핵심 인자인 C/EBPα, C/EBPβ 및 PPARγ의 발현량을 웨스턴 블럿 분석을 통해 분석함으로써, DM 추출물의 처리농도에 따른 C/EBPα, C/EBPβ 및 PPARγ의 발현량 변화를 확인한 결과, DM 추출물을 처리하지 않은 대조군(Con)의 경우에는 상기 C/EBPα, C/EBPβ 및 PPARγ이 모두 다량으로 검출되었으나, DM 추출물의 처리농도가 증가할 수록 상기 각 단백질의 함량이 감소됨을 확인하였다(도 5). 이는 본 발명의 DM 추출물이 지방생성에 관여하는 핵심인자의 발현을 저해하여, 항비만 활성을 나타냄을 시사하였다.
According to another embodiment of the present invention (Example 5), the effect of the anti-obesity composition of the present invention on lipogenesis-related proteins was analyzed. Specifically, the expression levels of C / EBPα, C / EBPβ and PPARγ, which are key factors involved in fat production in adipocytes treated with DM extract at various concentrations, were analyzed by western blot analysis, C / EBP?, C / EBP? And PPAR? Were detected in a large amount in the control group (Con) in which the DM extract was not treated, And the content of each protein was decreased as the treatment concentration was increased (FIG. 5). This suggests that the DM extract of the present invention inhibits the expression of key factors involved in fat production and thus exhibits anti-obesity activity.
본 발명의 또 다른 일 실시예에 의하면 (실시예 6), 본 발명의 항비만 조성물이 이미 생성된 지방세포에 대하여 어떠한 영향을 나타내는 지를 분석하였다. 구체적으로, 지방전구세포로부터 분화된 지방세포에 DM 추출물을 처리하고, 지방세포내의 중성지방(TG)의 함량과 배지로 분비된 글리세롤의 분비량을 측정한 결과, DM 추출물의 처리농도가 증가할 수록 지방세포내 중성지방(TG)의 함량이 감소하고 배지로 분비된 글리세롤의 분비량이 증가함을 확인하였다(도 6a 내지 6c). 이는 본 발명의 DM 추출물이 이미 형성된 지방세포내의 TG를 분해하여 항비만 활성을 나타냄을 시사하였다.
According to another embodiment of the present invention (Example 6), the effect of the anti-obesity composition of the present invention on already produced adipocytes was analyzed. Specifically, the DM extract was treated with adipocytes differentiated from adipose precursor cells, and the content of triglyceride (TG) in the adipocyte and the amount of glycerol secreted by the medium were measured. As the concentration of DM extract increased It was confirmed that the content of triglyceride (TG) in adipocytes was decreased and the amount of secreted glycerol in the medium was increased (Figs. 6A to 6C). This suggests that the DM extract of the present invention has anti-obesity activity by decomposing TG in already formed adipocytes.
본 발명의 항비만 조성물은 체중감소, 체지방감소, 혈중 중성지방 함량 감소 및 혈중 콜레스테롤 함량 감소의 효과를 가진다. 본 발명의 구체적인 실시예에 의하면 (실시예 4), IBMX (3-isobutyl-1-methylxanthine), 덱사메타손 및 인슐린을 포함하는 지방세포 분화배지를 이용하여 3T3-L1 지방전구세포의 분화를 유도한 경우, 상기 본 발명의 DM 추출물을 첨가하여 지방세포 생성을 억제함으로써 추출물의 농도에 따라 중성지방 함량이 감소하는 것을 확인할 수 있었다 (도 3 및 도 4).
The anti-obesity composition of the present invention has effects of weight loss, decrease of body fat, decrease of blood triglyceride content and decrease of blood cholesterol content. According to a specific example of the present invention (Example 4), when the differentiation of 3T3-L1 adipose precursor cells was induced using an adipogenic differentiation medium containing IBMX (3-isobutyl-1-methylxanthine), dexamethasone and insulin , And the DM extract of the present invention was added to inhibit the production of adipocytes, whereby the content of triglyceride was decreased according to the concentration of the extract (FIGS. 3 and 4).
추가적으로 상기 본 발명의 항비만 조성물은 지방생성을 억제함으로써, 비만뿐만 아니라 비만과 직간접적으로 관련된 지방간 또는 지질관련 심혈관 질환에 대한 예방 또는 치료의 효과를 나타낼 수 있다.In addition, the anti-obesity composition of the present invention can inhibit fat production, thereby showing effects of preventing or treating not only obesity but also fatty liver or lipid-related cardiovascular diseases directly or indirectly related to obesity.
본 발명의 용어 "지방간"은 지방질, 그 중에서도 특히 중성지방 (triglyceride)이 간세포에 축적되어 간 무게의 5% 이상을 차지하고 있는 질병이다. 음식물 등을 통하여 섭취한 지방질을 원활하게 처리하지 못하는 경우 발생하기도 하지만, 지방간을 일으키는 대표적인 원인은 술이다. 술은 간의 여러 가지 대사기능, 특히 지방산 산화 분해력을 감소시켜 간에 지방을 축적시킨다. 비만한 사람에게도 자주 지방간이 발생하며, 그 외, 당뇨병, 갑상선 기능 항진증 등의 내분비 질환, 스테로이드 호르몬의 과다 사용이나 심한 영양부족에 의해서도 발생할 수 있다. 특별한 증상이 없으므로 증상만으로 진단할 수 없으며, 간 질환의 일반적인 증상인 피로감, 식욕부진, 무기력 등이 나타날 수 있고, 오른쪽 갈비뼈 아래쪽에 불쾌감이나 둔통을 느끼기도 한다.The term " fatty liver "of the present invention is a disease in which fat, especially triglyceride, accumulates in hepatocytes and accounts for more than 5% of liver weight. However, the most common cause of fatty liver disease is alcohol. Alcohol reduces various metabolic functions of the liver, especially fatty acid oxidative degradation, and accumulates fat in the liver. Fatty liver often occurs in obese people, and it can also be caused by endocrine diseases such as diabetes, hyperthyroidism, overuse of steroid hormone, or severe nutritional deficiency. There are no special symptoms, so it is not possible to diagnose it by symptoms alone. Fatigue, anorexia and lethargy, which are common symptoms of liver disease, can occur and feel discomfort or dullness in the lower part of the right rib.
본 발명의 용어 "지질관련 심혈관 질환"은 지방산이나 콜레스테롤 등이 과도한 섭취나 대사 장애로 인해 축적되어 발생하는 질병이다. 특히 혈액 중의 중성지방의 농도가 비정상적으로 높아지는 고중성지방혈증은 미국 심장협회에 의해 심혈관질환의 위험인자로 규정되어 있다. 혈장중성지방은 식후 급격히 증가하여 약 8시간 후에는 식전 수준으로 돌아온다. 중성지방은 당뇨병, 비만, 음주자에서 증가하며 당분을 많이 섭취하는 사람에서도 증가한다. 그 외 갑상선 기능저하, 신증후군, 신부전증, 피임약 및 대량의 이뇨제와 베타차단제도 중성지방을 증가시킬 수 있다. 혈중중성지방이 증가할수록 LDL (low density lipoprotein) - 콜레스테롤이 증가하며, 상기 LDL은 죽상경화를 촉진시킨다. 상기 지질관련 심혈관 질환으로는 고지혈증, 심장병, 고혈압, 동맥경화증 등이 될 수 있다.
The term "lipid-related cardiovascular disease" of the present invention is a disease caused by accumulation of fatty acid or cholesterol due to excessive intake or metabolic disorder. Hypertriglyceridemia, in which the concentration of triglycerides in the blood is abnormally high, is defined by the American Heart Association as a risk factor for cardiovascular disease. Plasma triglyceride increases rapidly after meals and returns to the pre-meal level after about 8 hours. Triglycerides increase in diabetes, obesity, and drinkers, and increase in people who consume a lot of sugar. Other hypothyroidism, nephrotic syndrome, kidney failure, birth control pills, and large amounts of diuretics and beta blockers can also increase triglycerides. As the blood triglyceride increases, LDL (low density lipoprotein) - cholesterol increases and the LDL promotes atherosclerosis. Examples of the lipid-related cardiovascular diseases include hyperlipidemia, heart disease, hypertension, arteriosclerosis, and the like.
상기 본 발명의 약학조성물은 약학적으로 허용 가능한 담체를 추가로 포함할 수 있다. 본 발명의 용어 "약학적으로 허용 가능한"이란 상기 조성물에 노출되는 세포나 인간에게 독성이 없는 특성을 나타내는 것을 의미한다. 상기 담체는 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제, 기제, 부형제, 윤활제 등 당업계에 공지된 것이라면 제한 없이 사용할 수 있다. 또한 본 발명의 약학조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 나아가, 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태의 피부 외용제의 형태로 사용될 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 DM 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트 (calcium carbonate), 수크로즈 (sucrose) 또는 락토오즈 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" of the present invention means that it exhibits properties that are not toxic to the cells or humans exposed to the composition. Such carriers may be used without limitation as long as they are known in the art such as buffers, preservatives, wetting agents, solubilizers, isotonic agents, stabilizers, bases, excipients and lubricants. In addition, the pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method have. Furthermore, it can be used in the form of an external preparation for skin in the form of ointments, lotions, spray agents, patches, creams, powders, suspensions, gels or gels. Examples of carriers, excipients and diluents that can be contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, sucrose), lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are simple diluents commonly used in suspension, liquid solutions, emulsions and syrups have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 일 실시예에 따른 약학 조성물에 포함된 상기 DM 추출물의 함량은 특별히 이에 제한되지 않으나, 최종 조성물 총중량을 기준으로 0.0001 내지 50 중량%, 보다 바람직하게는 0.01 내지 10 중량%의 함량으로 포함할 수 있다.
The content of the DM extract contained in the pharmaceutical composition according to one embodiment of the present invention is not particularly limited but may be in the range of 0.0001 to 50% by weight, more preferably 0.01 to 10% by weight, based on the total weight of the final composition can do.
한편, 본 발명의 약학조성물은 약학적으로 유효한 양으로 투여한다. 본 발명의 용어 "투여"란, 적절한 방법으로 개체에게 소정의 물질을 도입하는 것을 의미하며 상기 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 국소 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있으나, 이에 제한되지는 않는다.Meanwhile, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administering" of the present invention means introducing a predetermined substance into an individual by an appropriate method, and the administration route of the composition can be administered through any conventional route so long as it can reach the target tissue. But are not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrathecal, rectal.
상기 용어 "개체"란 비만이 발병하였거나 발병할 수 있는 인간을 포함한 쥐, 생쥐, 가축 등의 모든 동물을 의미한다. 바람직하게는, 인간을 포함한 포유동물일 수 있다.The term "individual " refers to all animals, including mice, mice, livestock, etc., including humans who have developed or are capable of developing obesity. Preferably, it may be a mammal, including a human.
상기 용어 "약학적으로 유효한 양"이란 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효 용량 수준은 환자의 성별, 연령, 체중, 건강상태, 질병의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로, 및 배출 비율, 치료 기간, 배합 또는 동시에 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 당업자에 의해 용이하게 결정될 수 있다. 바람직하게 본 발명의 약학 조성물은 이에 포함된 DM 추출물을 기준으로 1일 0.0001 내지 100 ㎎/체중 kg으로, 바람직하게는 0.001 내지 100 ㎎/체중 ㎏으로 투여할 수 있다. 투여는 상기 권장 투여량을 하루에 한 번 투여할 수도 있고, 수 회 나누어 투여할 수도 있다.
The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, and the effective dose level is determined by the patient's sex, Including, but not limited to, medicaments and other medical fields that are used in combination, or in combination with, or in combination with, a pharmaceutically acceptable carrier, excipient, Can be readily determined by those skilled in the art according to known factors. Preferably, the pharmaceutical composition of the present invention can be administered at a dose of 0.0001 to 100 mg / kg of body weight per day, preferably 0.001 to 100 mg / kg of body weight per day based on the DM extract contained therein. The administration may be such that the recommended dose is administered once a day or divided into several times.
본 발명의 드라콘토멜론 마크로카펌 추출물은 천연 한약재를 원료로 하므로 식품 조성물, 화장료 조성물, 또는 약학적 조성물로 사용할 경우에도 일반적인 합성 화합물에 비하여 부작용이 덜할 수 있으므로 안전하게 포함되어 유용하게 사용될 수 있다.
The extract of Draconto melon mark Lokamper according to the present invention is used as a food composition, a cosmetic composition, or a pharmaceutical composition because it is a natural herbal medicine raw material, so it can be used safely and usefully because it has less side effects than general synthetic compounds.
상기 목적을 달성하기 위한 다른 실시양태로서, 본 발명은 DM 추출물을 유효성분으로 포함하는 비만 예방 또는 개선용 식품 첨가용 조성물을 제공한다.
As another embodiment for achieving the above object, the present invention provides a composition for preventing or improving obesity comprising DM extract as an active ingredient.
상기 본 발명의 DM 추출물은 항비만 효과를 나타낼 뿐만 아니라, 천연물로부터 유래되어 안전성이 입증되었으므로, 식품 첨가용 조성물로서 활용되어 비만 예방 또는 개선용 건강기능식품의 제조에 사용될 수 있다.
Since the DM extract of the present invention not only exhibits an anti-obesity effect but also has proven safety derived from natural products, it can be used as a composition for food addition and can be used for the production of a health functional food for prevention or improvement of obesity.
이처럼 식품 첨가물로 사용할 경우, 상기 DM 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상의 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있으며, 식품학적으로 허용 가능한 식품 보조 첨가제를 추가로 포함할 수 있다. 본 발명의 DM 추출물은 천연물로부터 유래되어 안전성 면에서 문제가 없기 때문에 식품에 첨가되는 함량은 특별히 제한되지 않으나, 바람직하게는 식품 조성물의 총 중량에 대하여 0.01 내지 90 중량%, 보다 바람직하게는 1 내지 60 중량%로 포함된다. 식품이 음료인 경우에는 100㎖를 기준으로 1 내지 30g, 바람직하게는 3 내지 20g의 비율로 포함될 수 있다. 또한, 상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신 (niacin), 비오틴 (biotin), 폴레이트 (folate), 판토텐산 (panthotenic acid) 등을 포함할 수 있다. 또한, 아연 (Zn), 철 (Fe), 칼슘 (Ca), 크롬 (Cr), 마그네슘 (Mg), 망간 (Mn), 구리 (Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제 (소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제 (표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제 (부틸히드록시아니졸 (BHA), 부틸히드록시톨류엔 (BHT) 등), 착색제 (타르색소 등), 발색제 (아질산 나트륨, 아초산 나트륨 등), 표백제 (아황산나트륨), 조미료 (MSG 글루타민산나트륨 등), 감미료 (둘신, 사이클레메이트, 사카린, 나트륨 등), 향료 (바닐린, 락톤류 등), 팽창제 (명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제 (호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물 (food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.
When used as a food additive, the DM extract may be added as it is or may be used together with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment), and may further include a food-acceptable food-aid additive. The DM extract of the present invention is derived from a natural product and has no problem in terms of safety. Therefore, the content added to the food is not particularly limited, but is preferably 0.01 to 90% by weight, more preferably 1 to 100% by weight, 60% by weight. When the food is a beverage, it may be contained in a proportion of 1 to 30 g, preferably 3 to 20 g based on 100 ml. In addition, the composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, vision and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like. In addition, it is also possible to use antiseptics (such as potassium sorbate, sodium benzoate, salicylic acid, and sodium dehydroacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (butylhydroxyanilide (BHA), butylhydroxytoluene BHT), etc.), coloring agents (such as tar pigments), coloring agents (such as sodium nitrite and sodium acetic acid), bleaching agents (sodium sulfite), seasoning (such as MSG sodium glutamate), sweeteners (such as hypoglycemia, , Food additives such as flavorings (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, emulsifiers, thickeners, encapsulating agents, gum bases, foam inhibitors, ) Can be added. The additives are selected according to the type of food and used in an appropriate amount.
본 발명의 식품 첨가용 조성물은 통상적인 식품의 제조시에 첨가물로서 사용되어 비만의 예방 또는 개선효과를 갖는 식품의 제조에 사용될 수 있고, 상기 식품 첨가용 조성물이 첨가된 식품은 기능성 식품, 건강기능식품 등 당업계에 알려진 용어와 혼용 가능하다.The food additive composition of the present invention can be used as an additive in the production of a conventional food, and can be used in the production of food having an effect of preventing or improving obesity. The food to which the food additive composition is added is a functional food, Food, and the like.
본 발명의 용어 "기능성 식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The term "functional food" in the present invention means a food prepared and processed by using a raw material or ingredient having functionality useful to the human body according to Law No. 6727 on health functional foods, and " And function of the nutrient for the purpose of obtaining a beneficial effect in health use such as controlling the nutrient or physiological action.
또한, 본 발명의 용어 "건강기능식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품 원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 상기 건강식품용 조성물은 질병의 예방 및 질병의 회복 등과 관련된 기능을 수행할 수 있다.
The term "health functional food" of the present invention refers to a food prepared by processing a specific ingredient as a raw material for the purpose of health assisting or by extracting, concentrating, refining, mixing, or the like a specific ingredient contained in a food raw material, Refers to a food which is designed and processed so that the body control function such as bio-defense, regulation of biorhythm, prevention and recovery of disease and the like can be sufficiently exhibited to the living body by the above components. Recovery, and so on.
본 발명의 조성물이 사용될 수 있는 식품의 종류에는 제한이 없다. 아울러 본 발명의 DM 추출물을 활성성분으로 포함하는 조성물은 당업자의 선택에 따라 식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다.There is no limitation on the kind of food in which the composition of the present invention can be used. In addition, the composition comprising the DM extract of the present invention as an active ingredient can be prepared by admixing other suitable auxiliary ingredients, which may be contained in food, with known additives according to the selection of a person skilled in the art. Examples of foods that can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen and other noodles, gums, ice creams, soups, beverages, tea, Vitamin complex, and the like, and can be prepared by adding to the juice, tea, jelly, and juice prepared from the extract of the present invention as a main component.
또한, 본 발명에 적용될 수 있는 식품에는 예컨대, 특수영양식품 (예: 조제유류, 영유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류 (예: 라면류, 국수류 등), 건강보조식품, 조미식품 (예: 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류 (예: 스낵류), 유가공품 (예: 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품 (각종 김치류, 장아찌 등), 음료 (예: 과실, 채소류 음료, 두유류, 발효음료류 등), 천연 조미료 (예: 라면스프 등) 등 모든 식품을 포함할 수 있다.Examples of foods that can be used in the present invention include special nutritive foods (such as crude oil, infant formula, etc.), processed meat products, fish meat products, tofu, jelly, noodles (such as ramen, (Such as fermented milk, cheese), other processed foods, kimchi, pickled foods (various kinds of kimchi, pickles, etc.), seasonings (such as soy sauce, soybean paste, , Beverages (such as fruit, vegetable beverages, beverages, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.).
본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.
When the health functional food composition of the present invention is used in the form of a drink, it may contain various sweeteners, flavors, or natural carbohydrates as an additional ingredient such as ordinary beverages. In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
본 발명의 드라콘토멜론 마크로카펌 (Dracontomelon macrocarpum, DM) 추출물을 포함하는 조성물은 지방전구세포의 지방세포로의 분화를 억제하고 췌장 리파아제 효소 활성을 억제시키는 능력을 가지므로 항비만 조성물로 유용하게 사용될 수 있으므로 지방간, 또는 지질관련 심혈관 질환과 같은 불필요한 지방의 축적으로 유발되는 질환의 예방 또는 치료를 위한 약학적 조성물 또는 비만 예방 또는 개선용 식품 첨가용 조성물로 이용될 수 있다.
The composition comprising the extract of Dracontomelon macrocarpum (DM) of the present invention has the ability to inhibit the differentiation of adipose precursor cells into adipocytes and inhibit the activity of pancreatic lipase enzyme, It can be used as a pharmaceutical composition for prevention or treatment of diseases caused by the accumulation of unnecessary fat such as fatty liver or lipid-related cardiovascular diseases, or a composition for preventing or improving obesity.
도 1은 본 발명의 DM 추출물의 췌장 리파아제 (pancreatic lipase) 효소 활성 저해능을 나타낸 그래프이다.
도 2는 본 발명의 DM 추출물의 세포 독성을 나타낸 그래프이다.
도 3은 본 발명의 DM 추출물의 농도 의존적 지방생성 억제를 확인하기 위하여, DM 추출물을 각각 다양한 농도(0, 5, 10, 25, 50, 75, 100 ㎍/㎖)로 첨가하여 분화시킨 3T3-L1 세포를 오일 레드 오 염색 (Oil red O staining)하여 현미경으로 관찰한 결과를 나타낸 사진이다.
도 4는 상기 도 3에서 염색된 오일 레드 오 염색 부위의 흡광도를 측정하여 계산한 중성지방 트리글리세라이드의 함량을 나타내는 그래프이다.
도 5는 본 발명의 DM 추출물의 처리농도에 따른 C/EBPα, C/EBPβ 및 PPARγ의 발현량 변화를 나타내는 웨스턴 블럿 분석사진이다.
도 6a는 본 발명의 DM 추출물의 처리농도에 따른 배지내 글리세롤의 분비량을 나타내는 그래프이다.
도 6b는 본 발명의 DM 추출물의 처리농도에 따른 지방세포의 변화를 나타내는 사진이다.
도 6c는 본 발명의 DM 추출물의 처리농도에 따른 지방세포내 중성지방(TG)의 함량변화를 나타내는 그래프이다. FIG. 1 is a graph showing the ability of the DM extract of the present invention to inhibit pancreatic lipase enzyme activity. FIG.
2 is a graph showing cytotoxicity of the DM extract of the present invention.
FIG. 3 is a graph showing the effect of the DM extract of the present invention on the inhibition of the concentration-dependent adipogenesis of 3T3-D, which is obtained by adding DM extracts at various concentrations (0, 5, 10, 25, 50, 75, 100 / / L1 cells were observed under a microscope by oil red o staining.
FIG. 4 is a graph showing the content of triglyceride triglyceride calculated by measuring the absorbance of the stained oil-red dyed area in FIG.
FIG. 5 is a Western blot analysis image showing the change in the expression level of C / EBP?, C / EBP? And PPAR? According to the treatment concentration of the DM extract of the present invention.
6A is a graph showing the secretion amount of glycerol in the medium according to the treatment concentration of the DM extract of the present invention.
6B is a photograph showing the change of adipocytes according to the treatment concentration of the DM extract of the present invention.
FIG. 6C is a graph showing changes in the content of triglyceride (TG) in fat cells according to the treatment concentration of the DM extract of the present invention. FIG.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
실시예 1: 드라콘토멜론 마크로카펌 (DM) 추출물의 제조Example 1 Preparation of Draconto Melon Mark Lokaperm (DM) Extract
DM 10 g을 파쇄하고, 이에 시료 부피의 5 내지 10배의 95% 메탄올을 가하여 75 ℃에서 추출한 다음, 여과하여 액상성분을 수득하는 과정을 3회 반복하여 추출액을 수득하였다. 상기 추출액을 감압농축기 (N-1000S-W, EYELA, Japan)에 적용하여 농축한 다음, 농축액을 동결건조 장치 (FDU2100, EYELA, Japan)에 적용하여 건조분말 형태의 DM 추출물을 수득하였다.
10 g of DM was disrupted, 95% methanol of 5 to 10 times the volume of the sample was added thereto, and the mixture was extracted at 75 DEG C and then filtered to obtain a liquid component. This procedure was repeated three times to obtain an extract. The extract was applied to a vacuum concentrator (N-1000S-W, EYELA, Japan) and concentrated. Then, the concentrate was applied to a lyophilizer (FDU2100, EYELA, Japan) to obtain a DM extract in the form of a dry powder.
실시예 2: DM 추출물의 췌장 리파아제 (pancreatic lipase) 효소 활성 억제능 분석Example 2: Inhibition effect of DM extract on pancreatic lipase enzyme activity
DM 추출물의 리파아제 활성 억제능 보유 유무를 알아보기 위해 각 추출물의 농도별 처리에 따른 리파아제의 활성 변화를 분석하였다. 리파아제는 주로 췌장에서 분비되어 중성지방인 트리글리세라이드 (Triglyceride, TG)를 글리세롤 (glycerol)과 지방산 (fatty acid) 으로 가수분해하는 효소로서 지방소화효소인 췌장 리파아제의 활성 저해능은 시료가 보유한 항비만 활성을 예측하기에 매우 유용한 시험법이다. 본 실시예에서는 각 시료의 항비만 활성을 세포 실험계에서 분석하기에 앞서 시료가 보유한 리파아제 효소 활성 저해능을 다음과 같이 측정하였다.To investigate the inhibitory effect of DM extracts on the lipase activity, we analyzed the activity of lipase by treatment with each concentration of each extract. Lipase is an enzyme that hydrolyzes triglyceride (TG), which is secreted from the pancreas and triglyceride (TG) into glycerol and fatty acid. The inhibitory activity of pancreatic lipase, a lipid digesting enzyme, This is a very useful test method to predict. In this example, the inhibitory activity of the lipase enzyme activity of the sample was measured as follows before analyzing the anti-obesity activity of each sample in a cell assay system.
먼저 1.5 ㎖ 튜브에 0.25 M Tris 완충액 (pH 7.7), 250 mM CaCl2, 5 mM 4-nitrophenyldodecanoate (PNPD)로 구성된 효소액과 기질을 넣고 잘 섞어준 후 37 ℃에서 5 분간 예열하고, 0.25 M Tris 완충액 (pH 7.7)에 녹인 리파아제와 다양한 농도의 DM 추출물을 넣어 37 ℃에서 10분간 반응시킨 후 20% sodium dodecyl sulfate (SDS)를 첨가하여 반응을 종료하였다. 반응액을 4 ℃, 15,000 rpm에서 20분간 원심 분리하여, 분리한 상층액을 96-웰 조직 배양 플레이트에 분주하고 멀티플레이트 리더 (multi-plate reader)를 이용하여 412 nm에서 흡광도를 측정한 후, 10분간 반응시킨 시료의 흡광도로부터 0분 반응 시료의 흡광도를 뺀 값을 시료 비처리 대조군 대비 백분율로 나타내었다. 측정값은 3회 반복 실험의 평균값으로 나타내었다 (도 1).First, an enzyme solution and a substrate composed of 0.25 M Tris buffer (pH 7.7), 250 mM CaCl 2 , and 5 mM 4-nitrophenyldodecanoate (PNPD) were added to a 1.5 ml tube and mixed thoroughly. The mixture was preheated at 37 ° C for 5 minutes and washed with 0.25 M Tris buffer (pH 7.7) and DM extracts at various concentrations were added to the reaction mixture at 37 ° C for 10 minutes, and the reaction was terminated by the addition of 20% sodium dodecyl sulfate (SDS). The reaction solution was centrifuged at 15,000 rpm for 20 minutes at 4 ° C. The separated supernatant was dispensed into a 96-well tissue culture plate and absorbance was measured at 412 nm using a multi-plate reader. The value obtained by subtracting the absorbance of the reaction sample at 0 minutes from the absorbance of the sample reacted for 10 minutes was expressed as a percentage of the sample untreated control group. The measured value was expressed as an average value of three repeated experiments (Fig. 1).
그 결과, 도 1에서 보듯이, DM 추출물 처리 농도의 증가에 따라 (0, 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 1 ㎍/㎖) 시료 비처리 대조군 대비 리파아제 활성이 감소됨을 확인함으로써 DM 추출물이 리파아제 활성을 농도 의존적으로 유의적으로 억제시키는 것을 확인하였다. 이러한 결과는 시료가 리파아제 저해제 (lipase inhibitor)로 작용하여 체내 지방 흡수율을 저하시켜 항비만 활성을 보유할 수 있다는 것을 의미한다.
As a result, as shown in FIG. 1, it was confirmed that the lipase activity was decreased compared to the sample-untreated control group (0, 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 1 ㎍ / It was confirmed that the extract significantly inhibited the lipase activity in a concentration-dependent manner. These results indicate that the sample acts as a lipase inhibitor to lower the absorption of fat in the body and thus possess antiobesity activity.
실시예 3: DM 추출물의 세포 독성 분석Example 3: Cytotoxicity analysis of DM extract
본 발명의 DM 추출물을 생체에서 안전하게 사용할 수 있는 지 여부를 확인하기 위하여 DM 추출물의 세포 독성 분석을 실시하였다. 마우스 지방전구세포 (preadipocyte) 세포주인 3T3-L1을 American Type Culture Collection (ATCC, USA) 으로부터 구입하여 10% 송아지 혈청 (bovine calf serum (BCS)) 및 페니실린/스트렙토마이신 (penicillin/streptomycin)이 포함된 DMEM (Dulbecco's modified eagle medium) 배지에서 배양하였다. 24 웰 조직 배양 플레이트에 웰 당 105 개의 세포를 분주하여 24 시간 동안 부착시키고 다양한 농도 (0, 1, 5, 10, 25, 50, 75, 100 ㎍/㎖)의 DM 추출물 용액으로 각각 처리하였다. 72시간 경과 후 DM 추출물을 포함하는 배지를 제거하고 WST (Water-soluble tetraolium salt) 시약을 포함하는 신선한 배지로 교체하여 37 ℃에서 30 분간 인큐베이션 하고 멀티플레이트 리더 (multiplate reader, Paradigm, Beckman, USA)를 이용하여 480 ㎚에서의 흡광도를 측정하였다 (도 2). 이때, 세포 생존율은 담체 (vehicle, dimethylsulfoxide, DMSO)를 처리한 대조군에 대한 %로 나타내었다.To determine whether the DM extract of the present invention can be safely used in vivo, the cytotoxicity analysis of the DM extract was conducted. 3T3-L1, a mouse preadipocyte cell line, was purchased from the American Type Culture Collection (ATCC, USA) and cultured with 10% calf serum (BCS) and penicillin / streptomycin And cultured in DMEM (Dulbecco's modified eagle medium) medium. 10 5 cells per well were plated on 24-well tissue culture plates for 24 h and treated with DM extract solutions at various concentrations (0, 1, 5, 10, 25, 50, 75, 100 ug / ml) . After 72 hours, the medium containing the DM extract was removed and replaced with fresh medium containing water-soluble tetraolium salt (WST) reagent. The plate was incubated at 37 ° C for 30 minutes, and a multiplate reader (Paradigm, Beckman, Absorbance at 480 nm was measured (Fig. 2). At this time, the cell survival rate was expressed as a percentage of the vehicle treated with vehicle (dimethylsulfoxide, DMSO).
그 결과, 도 2에서 보듯이, DM 추출물은 100 ㎍/㎖의 농도까지 세포독성을 전혀 유발하지 않는 안전한 물질임을 확인하였다.
As a result, as shown in FIG. 2, it was confirmed that the DM extract was a safe substance which did not induce cytotoxicity at all up to a concentration of 100 μg / ml.
실시예 4: DM 추출물의 지방생성 억제능 분석Example 4: Inhibitory effect of DM extract on lipogenesis
DM 추출물의 지방생성 억제효과를 확인하기 위하여, 지방세포로의 분화를 유도하고 그에 따른 지방생성 및 그 억제효과를 확인하였다.In order to confirm the effect of DM extract to inhibit lipogenesis, we induced the differentiation into adipocytes and confirmed lipogenesis and its inhibitory effect.
먼저, 3T3-L1 지방전구세포 (preadipocyte)를 0.5 μM 3-이소부틸-1-메틸크산틴 (3-isobutyl-methylxanthine; IBMX), 1 μM 덱사메타손 (dexamethasone; DEX) 및 10 ㎍/㎖ 인슐린 (insulin)을 포함하는 지방형성 분화배지에 배양하여 지방세포로의 분화를 유도하였다. 12 웰 조직 배양 플레이트에 웰 당 105 개의 세포를 분주하고 2일 후 10% 소 태아혈청 (fetal bovine syndrome, FBS)을 포함하는 배지로 교체하였다. 2일 경과 후 IBMX, DEX 및 인슐린을 포함하는 배지로 교환하면서 DM 추출물을 농도별로 처리하고 2일 간격으로 총 4회 인슐린 및 상기 추출물을 처리하고 2일 후 지방생성 억제능을 측정하였다.First, 3T3-L1 preadipocytes were incubated with 0.5 μM 3-isobutyl-methylxanthine (IBMX), 1 μM dexamethasone (DEX) and 10 μg / mL insulin ) To induce differentiation into adipocytes. 10 5 cells per well were plated on 12 well tissue culture plates and replaced with medium containing 10% fetal bovine syndrome (FBS) 2 days later. After 2 days, the DM extract was treated at different concentrations in the medium containing IBMX, DEX and insulin, and the insulin and the extract were treated 4 times at 2-day intervals, and the inhibitory effect on the fat production was measured 2 days later.
이때, 상기 지방생성 억제능은 다음과 같이 측정하였다: 지방세포로의 분화 유도 및 시료 처리가 완료된 세포를 1X 인산완충용액 (phosphate buffered saline, PBS)으로 세척한 다음 10% 포르말린 (formalin)으로 고정하고 오일 레드 오 염색 용액으로 처리한 후 30분 간 인큐베이션하였다. 염색이 완료된 후 100% 이소프로판올 (isopropanol)을 이용하여 세포에 침착한 염료를 추출하고 520 ㎚ 에서 상기 염료 추출액의 흡광도를 측정하였다 (도 3 및 도 4).The cells were washed with 1X phosphate buffered saline (PBS) and fixed with 10% formalin. The cells were washed with 1 ml of phosphate buffered saline (PBS) Red ocher solution and incubated for 30 minutes. After the dyeing was completed, the dye deposited on the cells was extracted with 100% isopropanol and the absorbance of the dye extract was measured at 520 nm (FIGS. 3 and 4).
그 결과, 도 3 및 도 4에 나타난 바와 같이 DM 추출물은 농도 의존적으로 중성지방 생성을 감소시키는 것을 확인하였다.As a result, as shown in FIG. 3 and FIG. 4, it was confirmed that DM extract decreased triglyceride production in a concentration-dependent manner.
상기 결과로부터, 본 발명의 DM 추출물이 지방 생성을 억제하는 효과를 나타냄을 알 수 있었다.
From the above results, it was found that the DM extract of the present invention has an effect of inhibiting lipogenesis.
실시예 5: 지방생성관련 단백질 분석Example 5: Analysis of lipogenesis-related proteins
실시예 4에서 지방세포로의 분화 유도 및 시료 처리가 완료된 세포를 파쇄하고, 이로부터 단백질을 분리한 다음, 지방생성에 관여하는 핵심 인자인 C/EBPα, C/EBPβ 및 PPARγ에 대한 각각의 항체를 이용한 웨스턴 블럿 분석에 적용하여, 본 발명의 추출물의 처리에 따른 상기 각 단백질의 발현량 변화를 분석하였다(도 5). 이때, 내부대조군으로는 액틴을 사용하였다.In Example 4, the cells that had been induced to differentiate into adipocytes and treated with the sample were disrupted, proteins were separated from the cells, and then the respective antibodies against C / EBP?, C / EBP? And PPAR? The Western blot analysis was used to analyze the expression amount of each protein according to the treatment of the extract of the present invention (FIG. 5). At this time, actin was used as an internal control group.
도 5에서 보듯이, 본 발명의 DM 추출물을 처리하지 않은 대조군(Con)의 경우에는 상기 C/EBPα, C/EBPβ 및 PPARγ이 모두 다량으로 검출되었으나, DM 추출물의 처리농도가 증가할 수록 상기 각 단백질의 함량이 감소됨을 확인하였다. As shown in FIG. 5, in the case of the control (Con) not treated with the DM extract of the present invention, all of the C / EBPα, C / EBPβ and PPARγ were detected in large amounts. However, And the protein content was decreased.
따라서, 본 발명의 DM 추출물은 지방생성에 관여하는 핵심인자의 발현을 저해함으로서 항비만 활성을 나타냄을 알 수 있었다.
Therefore, the DM extract of the present invention showed anti-obesity activity by inhibiting the expression of key factors involved in fat production.
실시예 6: 지방분해능 분석Example 6: Fat resolution analysis
105개의 3T3-L1 지방전구세포 (preadipocyte)를 12웰 플레이트에 각각 분주하여 2일 동안 배양하고, 10% FBS가 포함된 배지로 교체하여 다시 2일 동안 배양한 다음, 0.5μM IBMX, 1μM DEX 및 10 ㎍/㎖ 인슐린을 포함하는 지방형성 분화배지로 교체하여 2일 동안 배양하고, 지방형성 분화배지로 교환하고 2일 동안 배양하는 단계를 2회 추가로 수행하였다. 이때, 마지막으로 지방형성 분화배지로 교환할 때, 0, 5, 10, 25 또는 50㎍/㎖의 DM 추출물을 각각 추가하여 처리하였다. 최종 배양이 종료된 후, 배양상층액을 수득하여 배양상층액으로 분비된 글리세롤의 함량을 정량하고(도 6a), 분화된 지방세포를 Oil Red O staining을 통해 염색하였으며(도 6b), 지방세포내에 축적된 중성지방(TG)의 함량을 정량하였다(도 6c).10 5 3T3-L1 preadipocytes were each divided into 12-well plates, cultured for 2 days, replaced with medium containing 10% FBS, incubated again for 2 days, and then treated with 0.5 μM IBMX, 1 μM DEX And 10 쨉 g / ml insulin, for 2 days, exchanged with adipogenic differentiation medium, and incubated for 2 days. At this time, when the cells were finally replaced with an adipogenic differentiation medium, DM extracts of 0, 5, 10, 25 or 50 μg / ml were added, respectively. After completion of the final culture, a culture supernatant was obtained and the content of glycerol secreted into the culture supernatant was quantitated (Fig. 6A). The differentiated fat cells were stained with Oil Red O staining (Fig. 6B) (TG) was quantitated (Fig. 6C).
도 6a에서 보듯이, DM 추출물의 처리농도에 비례하여 배지로 분비되는 글리세롤의 분비량이 증가함을 확인하였고, 도 6b에서 보듯이, DM 추출물의 처리농도에 비례하여 Oil Red O staining을 통한 지방세포염색량이 감소함을 확인하였으며, 도 6c에서 보듯이, DM 추출물의 처리농도에 비례하여 지방세포내 중성지방(TG)의 함량이 감소됨을 확인하였다.As shown in FIG. 6A, it was confirmed that the secretion amount of glycerol secreted to the medium was increased in proportion to the treatment concentration of the DM extract, and as shown in FIG. 6B, in proportion to the treatment concentration of the DM extract, As shown in FIG. 6C, it was confirmed that the content of triglyceride (TG) in adipocytes was decreased in proportion to the treatment concentration of DM extract.
상기 도 6a 내지 6c의 결과는 본 발명의 DM 추출물의 처리를 통해 지방세포내 중성지방(TG)이 분해되어 분해산물인 글리세롤이 세포외부로 분비됨을 나타내었다.The results of FIGS. 6A to 6C show that glycerol, which is a degradation product, is secreted out of the cells through the treatment of the DM extract of the present invention.
따라서, 본 발명의 DM 추출물은 정상세포가 지방세포로 분화되는 것을 억제할 뿐만 아니라, 이미 분화된 지방세포내의 중성지방(TG)을 분해하여, 보다 효과적인 항비만 활성을 나타냄을 알 수 있었다.Therefore, the DM extract of the present invention not only inhibits differentiation of normal cells into adipocytes, but also decomposes triglyceride (TG) in already differentiated adipocytes, and thus shows more effective anti-obesity activity.
Claims (6)
A pharmaceutical composition for the prevention or treatment of obesity, comprising an extract of Dracontomelon macrocarpum (DM) as an active ingredient.
상기 DM 추출물의 함량은 최종 조성물 총중량을 기준으로 0.0001 내지 50 중량%인 것인 조성물.
The method according to claim 1,
Wherein the content of DM extract is from 0.0001 to 50% by weight, based on the total weight of the final composition.
상기 추출물은 탄소수 1 내지 4의 알코올, 에틸아세테이트, 아세톤, 헥산, 디클로로메탄 또는 이들의 혼합용매로 구성된 군으로부터 선택되는 용매로 추출하여 수득한 것인 조성물.
The method according to claim 1,
Wherein the extract is obtained by extracting with a solvent selected from the group consisting of alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, hexane, dichloromethane or a mixed solvent thereof.
상기 추출물은 95% 메탄올을 용매로 사용하여 65 내지 85℃의 온도에서 추출하여 수득한 것인 조성물.
The method according to claim 1,
Wherein the extract is obtained by extraction at a temperature of 65 to 85 캜 using 95% methanol as a solvent.
상기 추출물은 지방전구세포가 지방세포로 분화되는 것을 억제하는 것인 조성물.
The method according to claim 1,
Wherein the extract inhibits the lipid precursor cells from differentiating into adipocytes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126237A KR101501381B1 (en) | 2013-10-22 | 2013-10-22 | A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126237A KR101501381B1 (en) | 2013-10-22 | 2013-10-22 | A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101501381B1 true KR101501381B1 (en) | 2015-03-12 |
Family
ID=53027165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20130126237A KR101501381B1 (en) | 2013-10-22 | 2013-10-22 | A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101501381B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020251253A1 (en) * | 2019-06-10 | 2020-12-17 | 부산대학교 산학협력단 | Vital melon for preventing or treating obesity, and extract thereof |
WO2023106777A1 (en) * | 2021-12-10 | 2023-06-15 | 광동제약 주식회사 | Vital melon (kctc14699bp) and anti-obesity composition comprising extract thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101129621A (en) * | 2007-08-09 | 2008-02-27 | 倪慧文 | Anti-alcoholic medical tea |
-
2013
- 2013-10-22 KR KR20130126237A patent/KR101501381B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101129621A (en) * | 2007-08-09 | 2008-02-27 | 倪慧文 | Anti-alcoholic medical tea |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020251253A1 (en) * | 2019-06-10 | 2020-12-17 | 부산대학교 산학협력단 | Vital melon for preventing or treating obesity, and extract thereof |
WO2023106777A1 (en) * | 2021-12-10 | 2023-06-15 | 광동제약 주식회사 | Vital melon (kctc14699bp) and anti-obesity composition comprising extract thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120052138A1 (en) | Composition comprising green tea extract | |
JP5718468B2 (en) | Composition for suppressing obesity or lowering blood glucose, comprising Hariguwa and Yokuinin, and use thereof | |
KR102411434B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of radish leave | |
WO2015072674A1 (en) | Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases | |
KR101908221B1 (en) | Compositions for anti-obesity comprising extract of Cyperus microiria Steud. | |
KR101501381B1 (en) | A composition comprising Dracontomelon Macrocarpum extracts having anti-obesity activity | |
KR101445966B1 (en) | A composition comprising Amomum cardamomum L. extracts having anti-obesity activity | |
KR102416786B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave | |
US20220354918A1 (en) | Anti-obesity composition including geumhwagyu extract as active ingredient | |
KR20150012926A (en) | A composition comprising Chrysanthemum zawadskii extracts having anti-obesity activity | |
KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR20230014156A (en) | Composition for Anti-Obesity Comprising Catechin, and Complex Extracts of Rosa davurica Pall as Active Ingredient | |
KR101669717B1 (en) | Antiobesity composition comprising Capsicoside G | |
KR101501380B1 (en) | A composition comprising Euptelea Pleiosperma extracts having anti-obesity activity | |
KR20120130477A (en) | Composition comprising an extract of Akebiae Caulis for preventing and treating obesity | |
KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
KR20150046698A (en) | A composition comprising Salsola Collina extracts having anti-obesity activity | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
US11864575B2 (en) | Composition comprising low temperature water extract of hibiscus manihot for anti-obesity | |
KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
KR20150046699A (en) | A composition comprising Ardisia Arborescens extracts having anti-obesity activity | |
KR102411428B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of molokhia leave | |
KR101451473B1 (en) | Composition comprising an extract of Osterici Radix as an effective ingredient for treatment or prevention of diabetes | |
KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
KR101863603B1 (en) | Composition for prevention, improvement or treatment of arthritis comprising Mollugo pentaphylla extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190402 Year of fee payment: 5 |